Latest Information Update: 18 Nov 2003
At a glance
- Originator Nonindustrial source
- Class Phenylacetates
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glioma
Most Recent Events
- 18 Nov 2003 Discontinued - Phase-II for Glioma in USA (IV)
- 28 Apr 1999 Phase-II clinical trials for Glioma in USA (IV)